Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer

Previous studies suggest beta-adrenergic receptor (β-AR) antagonists (β-blockers) decrease breast cancer progression, tumor metastasis, and patient mortality; however the mechanism for this is unknown. Immunohistochemical analysis of normal and malignant breast tissue revealed overexpression of β1-A...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Montoya, Alexa, Amaya, Clarissa N., Belmont, Andres, Diab, Nabih, Trevino, Richard, Villanueva, Geri, Rains, Steven, Sanchez, Luis A., Badri, Nabeel, Otoukesh, Salman, Khammanivong, Ali, Liss, Danielle, Baca, Sarah T., Aguilera, Renato J., Dickerson, Erin B., Torabi, Alireza, Dwivedi, Alok K., Abbas, Aamer, Chambers, Karinn, Bryan, Brad A., Nahleh, Zeina
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2016
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5351644/
https://ncbi.nlm.nih.gov/pubmed/28031536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14119
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller